Chemoradiation with hyperthermia in the treatment of head and neck cancer

Figures & data

Table I.  Clinical profile.

Variable	n = 40 (%)
Age	30–70 yrs
Range	57.5 yrs
Median
Sex	37 (92.5%)
Male	03 (7.5%)
Female
Histopathology:
Squamous cell carcinoma	40 (100%)
Anatomical sub-sites	No. of patients
Oral cavity	12
Oropharynx	12
Larynx	2
Supraglottic larynx	3
Hypopharynx	8
Maxillary sinus	2
Nodal metastasis from unknown primary	1
Total	40

Mean age, 55.02; standard deviation, 10.50; median age, 57.5 years.

Table II.  Stratification according to TNM staging (AJCC).

Stage	N0	N1	N2	N3	Total
Tx	–	–	–	01 (2.5%)	01 (2.5%)
T1	–	–	–	–
T2	02 (5%)		02 (5%)	02 (5%)	06 (15%)
T3	09 (22.5%)		03 (7.5%)	04 (10%)	16 (40%)
T4	07 (17.5%)	01 (2.5%)	02 (5%)	07 (17.5%)	17 (42.5%)
Total	18 (45%)	01 (2.5%)	07 (17.5%)	14 (35%)	40 (100%)

Table III.  Details of frequency of hyperthermia and chemotherapy sessions with radiation therapy in 40 patients of head and neck cancer.

Number of hyperthermia sessions
No. of fraction	Frequency (n)	%
<3	3	7.5
4–7	37	92.5
Total	40	100
Chemotherapy sessions
Chemo cycles	Frequency (n)	%
<3	04	10
4–7	36	90
Total	40	100

Table IV.  Drug-wise initial response of patients.

Drug	No. of patients	CR (%)	PR (%)
Cisplatin	20	13 (34.21%)	07 (18.42%)
Paclitaxel	18	16 (42.01%)	02 (5.26%)
Total	38	29 (76.31%)	09 (23.68%)

Figure 1. Kaplan-Meier survival estimates following chemoradiation and hyperthermia.